Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Nov;100(11):1617-1627.
doi: 10.1007/s00109-022-02244-w. Epub 2022 Sep 19.

The serotonin receptor 3E variant is a risk factor for female IBS-D

Affiliations
Meta-Analysis

The serotonin receptor 3E variant is a risk factor for female IBS-D

Nikola Fritz et al. J Mol Med (Berl). 2022 Nov.

Abstract

Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT3 receptor family. 5-HT3Rs are encoded by HTR3 genes and control GI function, and peristalsis and secretion, in particular. Moreover, 5-HT3R antagonists are beneficial in the treatment of diarrhea predominant IBS (IBS-D). We previously reported on functionally relevant SNPs in HTR3A c.-42C > T (rs1062613), HTR3C p.N163K (rs6766410), and HTR3E c.*76G > A (rs56109847 = rs62625044) being associated with IBS-D, and the HTR3B variant p.Y129S (rs1176744) was also described within the context of IBS. We performed a multi-center study to validate previous results and provide further evidence for the relevance of HTR3 genes in IBS pathogenesis. Therefore, genotype data of 2682 IBS patients and 9650 controls from 14 cohorts (Chile, Germany (2), Greece, Ireland, Spain, Sweden (2), the UK (3), and the USA (3)) were taken into account. Subsequent meta-analysis confirmed HTR3E c.*76G > A (rs56109847 = rs62625044) to be associated with female IBS-D (OR = 1.58; 95% CI (1.18, 2.12)). Complementary expression studies of four GI regions (jejunum, ileum, colon, sigmoid colon) of 66 IBS patients and 42 controls revealed only HTR3E to be robustly expressed. On top, HTR3E transcript levels were significantly reduced in the sigma of IBS patients (p = 0.0187); more specifically, in those diagnosed with IBS-D (p = 0.0145). In conclusion, meta-analysis confirmed rs56109847 = rs62625044 as a risk factor for female IBS-D. Expression analysis revealed reduced HTR3E levels in the sigmoid colon of IBS-D patients, which underlines the relevance of HTR3E in the pathogenesis of IBS-D.

Keywords: Females; IBS-D; Irritable bowel syndrome; Serotonin type 3 receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Schematic of the HTR3 genes indicating the location and type of the analyzed SNPs. The gray box indicates the coding sequence of a HTR3 gene. The upstream region of the start codon AUG (5′untranslated region [5′UTR]) is indicated by the thin line on the left, whereas the respective 3′ untranslated region resides downstream of the stop codon, illustrated by an asterisk on the right. CDS, coding sequence (protein coding portion)
Fig. 2
Fig. 2
Forest-plots illustrating genotype relative risks of IBS phenotypes were quantified by odds ratios with corresponding 95% confidence intervals (indicated by lower and upper limit) based on a logistic regression model under dominant genetic penetrance for all but HTR3C. We assumed that the identified studies were random samples from a general population, and therefore used a random effects model to summarize odds ratio estimates in the meta-analyses of the respective gene SNP. Confidence intervals for each individual study were indicated by horizontal lines, single ORs by squares that reflected study sizes, and summary estimates by diamonds with horizontal limits at confidence limits and width inversely proportional to the standard error
Fig. 3
Fig. 3
qPCR analysis of total RNA isolated from various GI regions including A jejunum, B ileum, C colon, and D, E sigmoid colon. Samples were run in triplicate and data analyzed by the 2-∆∆Ct method with correction for primer efficiency. Two-tailed parametric tests were used as appropriate (unpaired t test, one-way ANOVA followed by Bonferroni correction post-hoc test) using GraphPad Prism 5.0 software

References

    1. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R (2016) Bowel Disorders. Gastroenterol. 10.1053/j.gastro.2016.02.031 - PubMed
    1. Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilic-Stojanovic M, Schemann M, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. doi: 10.1038/nrdp.2016.14. - DOI - PMC - PubMed
    1. Spiller R, Major G. IBS and IBD—separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13:613–621. doi: 10.1038/nrgastro.2016.141. - DOI - PubMed
    1. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S et al (2020) Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterol. 10.1053/j.gastro.2020.04.014 - PubMed
    1. Black CJ, Ford AC (2020) Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 10.1038/s41575-020-0286-8 - PubMed

Publication types